As the leading voice for home infusion on Capitol Hill and with the Administration, NHIA is fighting to ensure that federal policy supports equitable access to the full range of home infusion therapies.
Current Policy Initiatives
Preserving Patient Access to Home Infusion Act (116th Congress)
In 2016, Congress passed the 21st Century Cures Act, which included reforms to the Medicare Part B DMEPOS program including changing the payment methodology for drugs from Average Wholesale Price to Average Sales Price. To ensure home infusion services were not interrupted, Congress added a new Home Infusion Therapy Services benefit to Medicare Part B. Since the new benefit created by Cures does not start until 2021, Congress included a home infusion services temporary, transitional benefit in the Bipartisan Budget Act of 2018, in an effort to bridge the gap until the permanent benefit would begin.
Unfortunately, the Centers for Medicare and Medicaid Services (CMS) has interpreted the home infusion services benefit as one that covers professional services provided in the patient’s home (i.e. nursing) to administer IV or SC medications. Despite a letter from the Congressional sponsors of the home infusion legislation, numerous comments through the rule-making process, and drops in utilization, CMS has not moved from their flawed definition of “home infusion calendar day.”
NHIA has drafted legislation with the help of our Congressional champions to permanently fix the home infusion therapy services benefit. The legislation (H.R. 6218, S. 3457) was introduced in March 2020 and will accomplish the following if passed:
How you can help
In addition to the work NHIA has done on Medicare Reimbursement, we have been active on issues related to sterile compounding, insanitary conditions, and revisions to USP <797> and <800>. Click here for additional information on these activities.